DermaXon is a Missoula-based preclinical-stage pharmaceutical company focused on the discovery and development of novel therapeutic strategies to treat and prevent life-threatening chronic diseases such as Alzheimer’s disease, ichtyosis and neuropathic pain. DermaXon has an innovative chemical entities pipeline targeting nuclear receptors, calcium channels and cytochrome CYP26s. We have identified two active small molecules inhibiting the metabolism of retinoic acid to restore its biological effects in the brain or in the skin. The two other preclinical molecules in the pipeline targets a specific calcium channel and a nuclear receptors and exploits a unique approach for the treatment of respectively peripheral neuropathy and skin disorders. DermaXon has received several grants including Small Business Technology Transfer (STTR) awards from the NIH and a Rapid Response Innovation Award from the Michael J Fox Foundation for Parkinson Research.